First Reporting Quarter as Valion Bio Marked by Continued Advancement of the Entolimod Platform, Broader Government Engagement, and Continued Integration of Velocity ...

Adaptin Bio, Inc. (OTCQB: APTN), (“Adaptin” or the “Company”), a biotechnology company developing precision cancer ...

Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV® study presented today at ASGCT 2026 Annual Meeting along with initial ...

An emphasis on emotional depth and cultural nuance within the design process is among the priorities in creative education, ...

Call of Cthulhu's Chaosium and others have condemned 4 Pillar Games' rampant AI use in what it calls a tabletop "historical ...

Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced significant updates to two ...

Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of teli ...

Phase 2b study design to be discussed at BIO International Convention in San Diego as Can-Fite advances partnership ...

Scientists who focus only on generating data risk missing their role in shaping strategy and driving innovation.

Kyntra Bio, Inc. (NASDAQ: KYNB) Q1 2026 Earnings Call Transcript May 11, 2026 Kyntra Bio, Inc. misses on earnings expectations. Reported EPS is $-3.76 EPS, expectations were $-3.36.

Compared with Q4 2025, management’s interim-readout language shifted from “the second half of 2026” to “the fourth quarter of 2026,” with CEO Wettig now stating “we are on track for the interim ...

Good afternoon, everyone, and thank you for joining us today to discuss Kyntra Bio, Inc.’s first quarter 2026 financial and business results. I am Gaia Vasiliver-Shamis from LifeSci Advisors. Joining ...